Fresh analysis indicates that individuals who discontinue new slimming jabs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional diet and exercise programs.
Findings released in a leading health publication shows that while obese individuals often shed substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such drugs must be cognizant of the potential of rapid weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about a year and a half.
Comparing Treatments
The research, which reviewed 37 of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.
Scientists emphasize that people who lose weight through dieting generally see a less rapid creep back—approximately 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Nutrition scientists believe the way of the injections accounts for the heightened rebound.
The injections imitate a body's own chemical called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 levels far above than normal may cause the system to produce less of its own natural hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, given the likelihood of relapse, the therapy is often life-long.
This view is reinforced by drug manufacturers, who state that the findings "emphasize the chronic character of excess weight," similar to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the jabs report a powerful return of cravings.
"I experienced a trigger flipping and you're instantly starving," recalled an individual.
This difficulty is worsened if users have not developed sustainable lifestyle or habit modifications during therapy.
Significant Interest
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is more common among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic fix and long-term success relies on combined lifestyle support.
